853076-92-3

Upstream product

• 853076-89-8 5-hydroxy-8-(2-methoxycarbonyl-ethyl)-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester 
• 328918-86-1 toluene-4-sulfonic acid 2-(2-biphenyl-4-yl-5-methyloxazol-4-yl)ethyl ester 
• 2439-04-5 5-hydroxyisoquinoline 
• 216064-48-1 2-tert-butyloxycarbonyl-5-hydroxy-1,2,3,4-tetrahydroisoquinoline 
• 24424-99-5 di-tert-butyl dicarbonate 
• 102877-50-9 1,2,3,4-tetrahydro-5-hydroxy-isoquinoline 
• 853074-91-6 tert-butyl 5-(benzyloxy)-8-bromo-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 497068-68-5 tert-butyl 8-bromo-5-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxylate 

Downstream Products

• 853076-93-4 3-{5-[2-(2-biphenyl-4-yl-5-methyl-oxazol-4-yl)-ethoxy]-l,2,3,4-tetrahydro-isoquinolin-8-yl}-propionic acid methyl ester 
• 853076-94-5 5-[2-(2-biphenyl-4-yl-5-methyl-oxazol-4-yl)-ethoxy]-8-(2-methoxycarbonyl-ethyl)-3,4-dihydro-1H-isoquinoline-2-carboxylic acid propyl ester 

Relevant academic research and scientific papers

Tetrahydroisoquinoline PPARγ agonists: Design of novel, highly selective non-TZD antihyperglycemic agents

Novel tetrahydroisoquinolines have been developed as potent PPAR ligands. Evaluation of these compounds in PPARγ responsive models of type 2 diabetes is described.

HETEROCYCLIC COMPOUNDS AS MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS, USEFUL FOR THE TREATMENT AND/OR PREVENTION OF DISORDERS MODULATED BY A PPAR

The present invention is directed to a compound of formula (I), or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, which is useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.